Stocktoria
SpyGlass Pharma, Inc. SGP
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2026-02-06
SpyGlass Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $29.2M | $20.0M |
| Operating income | -$41.4M | -$27.1M |
| Income tax | $0 | $0 |
| Net income | -$39.9M | -$29.2M |
| EPS (diluted) | $-17.98 | $-16.31 |
| Operating cash flow | -$32.7M | -$22.0M |
| Free cash flow | -$33.5M | -$24.0M |
| Cash & equivalents | $96.4M | $16.3M |
| Total assets | $115.9M | $23.3M |
| Total liabilities | $10.2M | $11.2M |
| Shareholders' equity | -$98.8M | -$60.5M |
Source: SEC EDGAR filings · CIK 0001778922 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.